The outcome of patients with myelodysplastic syndromes (MDSs) after failure of hypomethylating agents (HMAs) failure is poor with a median overall survival (OS) of only 4-6 months. Omacetaxine mepesuccinate (OM) is safe and effective in myeloid malignancies but has not been studied in MDS with HMA failure. We conducted a phase II study of OM in patients with MDS or chronic myelomonocytic leukemia (CMML) who had previously failed or been intolerant to HMAs. Patients received OM at a dose of 1.25 mg/m 2 subcutaneously every 12 hours for 3 consecutive days on a 4-to 7-week schedule. The primary endpoints were the overall response rate (ORR) and OS. A total of 42 patients were enrolled with a median age of 76 years. The ORR was 33%. Patients with diploid cytogenetics were more likely to respond to OM than were those with cytogenetic abnormalities (58% vs 23%, respectively; P = .03). Overall, the median OS was 7.5 months and 1-year OS rate was 25%. Patients with diploid cytogenetics had superior OS to those with cytogenetic abnormalities (median OS 14.8 vs 6.8 months, respectively; P = .01).
| INTRODUCTION
For patients with higher-risk myelodysplastic syndromes (MDSs) and chronic myelomonocytic leukemia (CMML), the use of hypomethylating agents (HMAs) such as azacitidine and decitabine is standard of care. 1, 2 Responses are achieved in up to 40% of patients; however, HMA therapy is not curative and patients nearly universally lose response. For patients who do not respond to HMAs or who subsequently relapse, the outcomes are dismal with a median overall survival (OS) of only 4-6 months for patients with higher-risk MDS. 3, 4 In the setting of MDS with HMA failure, there is no clear standard of care.
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Omacetaxine mepesuccinate (OM), or semisynthetic homoharringtonine (HHT), is a protein synthesis inhibitor that inhibits protein translation via interaction with the ribosomal A-site. 5 This leads to downregulation of proteins that regulate cell proliferation and survival, eventually leading to apoptosis of leukemic cells. HHT and OM are active in a variety of myeloid malignancies, including chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and MDS. Several older studies have evaluated HHT in patients with AML and MDS using continuous intravenous (IV) infusions of higher doses of HHT.
Using doses of 5-7 mg/m 2 IV continuously for 7-9 days, complete response (CR) rates of 16%-25% were achieved in patients with relapsed or refractory AML. 6, 7 In a frontline study of HHT in MDS or AML arising from MDS, the CR rate was 25%. 8 In another small pilot study of HHT in patients with MDS, 1 of 9 patients (11%) achieved CR. 9 Despite its clinical activity, these high doses of continuous IV
HHT resulted in high rates of myelosuppression and cardiovascular toxicity, including severe hypotension and tachycardia, which limited its development for these diseases.
Given the excellent bioavailability of subcutaneous OM and its ability to be administered in the outpatient setting, 10 
| Gene sequencing
Mutation analysis was performed using a 28-gene panel as previously described within 2 months prior to enrollment. [15] [16] [17] Genomic DNA was extracted from bone marrow aspirates or peripheral blood. 
| Statistical methods
The primary objectives of this phase II study were the overall response rate (ORR) and OS of the regimen. 
| Response rates
A total of 14 patients (33%) had a response to OM: 13 (31%) achieved marrow CR and 1 achieved HI (2%). One of the thirteen patients who achieved marrow CR also met criteria for HI of neutrophils. The median number of cycles to best response was 2 (range, 1-9 cycles).
Six patients (14%) had stable disease and received 4 cycles (n = 4), Patients with diploid cytogenetics had a significantly higher response rate to OM than did patients with cytogenetic abnormalities (58% vs 23%, respectively; P = .03). Among the 17 patients with poor-risk cytogenetics, 4 patients responded to OM (24%). No differences in response were observed according to presence of either TP53 mutation (25% vs 37% for wild type; P = .47) or RUNX1 mutation (45% vs 30% for wild type; P = .36).
| Survival outcomes
With a median duration of follow-up of 25 months, the median RFS was 5.3 months, and the 1-year RFS rate was 34% (Figure 2A ). Of the 14 responders, 4 remain on study, 7 subsequently lost response, 2 died while in response (both from infection-related complications), and 1 was lost to follow-up. No patients underwent subsequent hematopoietic stem cell transplantation. Among the 7 patients who lost response, the median time to relapse was 5.0 months (range, 2.9-8.5 months).
The median OS was 7.5 months and 1-year OS rate was 25%
( Figure 2B) 
KRAS/NRAS 3 (7)
IDH1/2 2 (5)
No mutations identified 9 (21) a Mutations identified in at least 2 patients are included in the table.
30 months. Both of these patients had MDS with diploid cytogenetics and RUNX1 mutation.
| Treatment intensity, safety, and early mortality
The median number of cycles of OM received was 3 (range, 1-23 cycles).
Four patients (10%) received treatment with OM for at least 1 year. Table 2 shows the adverse events observed in patients treated on this study. Treatment was overall well-tolerated with most adverse events being grade 1-2. Grade ≥ 3 adverse events were observed in 15 patients (36%). The most common grade ≥ 3 adverse events were infections in 11 patients (26%), febrile neutropenia in 4 (10%), and hemorrhage in 3 (7%). The infections included pneumonia (n = 6), sepsis (n = 2), bacteremia (n = 1), urinary tract infection (n = 1), and upper respiratory tract infection (n = 1). Of the hemorrhagic episodes, 2 were upper gastrointestinal bleeding and one was subarachnoid hemorrhage after a fall. Of 39 patients who received ≥2 cycles of OM, 8 (21%) required dose reduction. The 30-and 60-day mortality rates were 10% and 14%, respectively.
| DISCUSSION
The outcomes of patients with high-risk MDS who experience HMA failure is poor, with a median OS of only 4-6 months, and there is no standard of care for these patients. Outside of a clinical trial, therapeutic options for patients with high-risk MDS with HMA failure include switch to an alternative HMA (eg, azacitidine to decitabine, or vice versa) or combination chemotherapy. 19 However, HMA switch is associated with a modest response rate of only approximately 20%
with responses being generally short-lived. 20 Chemotherapy is generally reserved for fit patients without adverse-risk karyotype or mutations. In one study of MDS with HMA failure, low-dose chemotherapy resulted in no responses (out of 18 patients), whereas the response rate with intensive chemotherapy was 14% (3 out of 22 patients). 4 Allogeneic stem cell transplantation appeared to result in the best responses for these patients (response rate of 68%), although this is a viable option for only a small minority of patients due to the relatively In the present study, OM was found to be safe and active in patients with MDS or CMML who experienced HMA failure, with an ORR of 33% and median OS of 7.5 months. Of note, this was a particularly poor-risk group of patients, with a median age of 76 years, 40% of patients with poor-risk cytogenetics, 45% having received at least 2 prior therapies. Despite these poor-risk features, the OS in this study was better than that reported in other studies of MDS with HMA failure. 3, 4 This favorable survival appears to be largely driven by response to OM, given that responders had a significantly longer 1-year OS rate than did non-responders (41% vs 16%). It is notable that 2 patients had prolonged benefit from OM therapy, with survival of 2 or more years.
Although 13 of the 14 responders achieved marrow CR, no CRs were observed. There are 2 potential explanations for the incomplete HI observed in these responders to OM. One possibility is that this incomplete count recovery may in part be explained by the myelosuppressive effects of OM, as grade ≥ 3 thrombocytopenia, neutropenia, or anemia were reported in 68%, 46%, and 36% of patients, respectively, who were treated with OM for chronic phase CML. 21 However, the doses of OM used in this study were significantly lower than those used in CML (ie, 3-day regimen vs 14-day induction and 7-day consolidation regimen), and therefore the myelosuppressive effects of OM are expected to be less.
Alternatively, responses to OM may not have been sufficiently deep to lead to full count recovery. This is suggested by the fact that only 1 out of 7 responders achieved a complete cytogenetic response at the time of best response; this level of cytogenetic response may act as a kind of marker of minimal residual disease and is associated with more durable remissions and prolonged survival in patients with MDS treated with HMAs. 22, 23 Although there is no standard of care regimen for patients with MDS and HMA failure, several agents and combination regimens have shown promise in this setting. These include novel HMAs (eg, guadecitabine), immune check point inhibitors (eg, nivolumab, pembrolizumab, and ipilimumab), Bcl-2 inhibitors (eg, venetoclax) and multikinase inhibitors (eg, rigosertib), among others. 19 Low-dose chemotherapy combinations are also effective in MDS after HMA failure. In one study, the combination of clofarabine and low-dose cytarabine resulted in an ORR of 44% and a median OS of 10 months. 24 Similar to the present study in which patients with diploid cytogenetics were more likely to respond to OM than were patients with other cytogenetic abnormalities (58% vs 23%, respectively), the response rate among patients with diploid karyotype treated with clofarabine plus low-dose cytarabine was 64%.
It is notable that the ORR with this combination regimen appears superior to that achieved with single-agent oral clofarabine, in which a response rate of 30% was reported in patients with HMA failure. 25 Similarly, the addition of other agents (eg, clofarabine, low-dose cytarabine, rigosertib, etc.) may further improve the responses with OM.
In conclusion, in patients with MDS or CMML who experienced HMA failure, OM resulted in an ORR of 33% and a median OS of 7.5 months. Although responses were observed across cytogenetic risk groups, patients with diploid cytogenetics were most likely to respond, with an ORR of 58% in this subgroup, and some patients experienced durable responses of 2 years or more. Given the lack of effective options for patients after HMA failure, these results support the further development of OM in this setting, including combination therapies.
